^
    2d
    Fostamatinib (R788), a spleen tyrosine kinase inhibitor, sensitizes pancreatic cancer cells to oncolytic vesicular stomatitis virus. (PubMed, Mol Ther Oncol)
    Additionally, fostamatinib inhibited PDAC cell proliferation even in the absence of viral infection, while ruxolitinib did not. Our data suggest that fostamatinib may be repurposed as an effective drug that enhances OV therapy in PDAC by promoting OV replication and suppressing tumor growth.
    Journal
    |
    SYK (Spleen tyrosine kinase)
    |
    Jakafi (ruxolitinib) • Tavalisse (fostamatinib)
    4d
    Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov)
    P1/2, N=39, Recruiting, University of Michigan Rogel Cancer Center | Trial completion date: Oct 2029 --> Jan 2030 | Trial primary completion date: Oct 2027 --> Jan 2028
    Trial completion date • Trial primary completion date
    |
    Xtandi (enzalutamide) • Jakafi (ruxolitinib)
    4d
    Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell Lymphoma (clinicaltrials.gov)
    P4, N=40, Recruiting, The First Affiliated Hospital of Soochow University
    New P4 trial
    |
    Rituxan (rituximab) • Jakafi (ruxolitinib) • Brukinsa (zanubrutinib)
    4d
    Omics and artificial intelligence integration for stratifying blast crisis CML using COSMIC signatures and pan-cancer precision drug repurposing. (PubMed, World J Clin Oncol)
    This WES-AI-ML framework provides mutation-guided therapies for BC-CML, enabling real-time stratification and Food and Drug Administration-approved drug repurposing. While this exploratory study is limited by its small sample size (n = 7), it establishes a methodological framework for precision oncology stratification that warrants validation in larger, multi-center cohorts.
    Journal • Tumor mutational burden • BRCA Biomarker • PARP Biomarker • Pan tumor
    |
    TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • BRCA2 (Breast cancer 2, early onset) • BCR (BCR Activator Of RhoGEF And GTPase) • CSF3R (Colony Stimulating Factor 3 Receptor)
    |
    Lynparza (olaparib) • Jakafi (ruxolitinib) • Tibsovo (ivosidenib)
    8d
    Understanding Cardiovascular Events With JAK Inhibitors: Similarities and Differences of the Vascular Effects Between Different JAK Inhibitors on Endothelial Cells Exposed to Inflammatory Cytokines. (PubMed, ACR Open Rheumatol)
    All JAKi reduced EC inflammation but most JAKi could not prevent the up-regulation of adhesion molecules or the increase in procoagulant and the decrease in anticoagulant factors triggered by proinflammatory cytokines. Peficitinib and fedratinib exhibited cytotoxic effects causing EC apoptosis.
    Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • ICAM1 (Intercellular adhesion molecule 1) • IL17A (Interleukin 17A) • VCAM1 (Vascular Cell Adhesion Molecule 1) • ANXA5 (Annexin A5)
    |
    Jakafi (ruxolitinib) • Inrebic (fedratinib) • tofacitinib
    9d
    A Novel, Ruxolitinib-Sensitive, CCDC6::JAK2 Fusion Gene in a Patient With Atypical, JAK2 Unmutated, Polycythemia Vera-Like, Myeloproliferative Neoplasm. (PubMed, Am J Hematol)
    The CCDC6::JAK2 chimeric protein retains the CCDC6 coiled-coil domain and the JAK2 kinase domain. Dimerization of chimeric proteins through coiled-coil domains promotes JAK2 autophosphorylation leading to constitutive activation of the JAK/STAT signaling pathway.
    Journal
    |
    JAK2 (Janus kinase 2) • CCDC6 (Coiled-Coil Domain Containing 6)
    |
    Jakafi (ruxolitinib)
    10d
    Targeting DESI2 as a Novel Therapeutic Strategy for JAK2-Mutant Leukemias. (PubMed, Adv Sci (Weinh))
    Although the JAK1/2 inhibitor Ruxolitinib is clinically approved, its efficacy is limited by toxicity to normal cells and the development of drug resistance...Moreover, through a compound screen, followed by chemical proteomics and compound optimization, WWQ-03-012 is discovered, which selectively degrades mutant JAK2, induces primary leukemia cells death, and inhibits MPN progression through targeting DESI2 enzymatic activity in vitro and in vivo. These studies provide a novel therapeutic strategy against mutated JAK2 signaling in MPN and sAML.
    Journal
    |
    JAK2 (Janus kinase 2)
    |
    Jakafi (ruxolitinib)
    16d
    RUX-HAPLO: Ruxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Disease (clinicaltrials.gov)
    P1/2, N=24, Not yet recruiting, University of Colorado, Denver
    New P1/2 trial
    |
    Jakafi (ruxolitinib) • cyclophosphamide • sirolimus
    17d
    CINC424C2416: Study of Efficacy and Safety of Ruxolitinib in Patients With Grade II to IV Steroid-refractory Acute Graft vs. Host Disease (clinicaltrials.gov)
    P4, N=36, Recruiting, Novartis Pharmaceuticals | N=54 --> 36
    Enrollment change
    |
    Jakafi (ruxolitinib)
    18d
    AURORA: Safety, PK, PD, Dosing, and Efficacy of RLS-0071for the Treatment of Hospitalized Patients With Steroid-Refractory Acute Graft-versus-Host Disease (clinicaltrials.gov)
    P2, N=66, Recruiting, ReAlta Life Sciences, Inc. | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Oct 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    Jakafi (ruxolitinib)
    18d
    HEMA-MED: A Study of Roginolisib in Combination With Ruxolitinib in Patients With Myelofibrosis (MF) Who Are Unresponsive to JAK Inhibitors (clinicaltrials.gov)
    P1/2, N=26, Recruiting, iOnctura | Initiation date: May 2025 --> Nov 2025
    Trial initiation date
    |
    Jakafi (ruxolitinib) • roginolisib (IOA-244)